Ciprofloxacin and antibacterial therapy of respiratory tract infections

Antibiotiki i Khimioterapiya

Volumn 51, Issue 5, 2006, Pages 29-37

  Ivanov, D V ^a   Budanov, S V ^a  

^a NONE

Author keywords

Ciprofloxacin; Fluoroquinolones; Respitatory tract infections

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE;

BACTERIAL INFECTION; BACTERIUM; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MICROBIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CIPROFLOXACIN; DNA GYRASE; FLUOROQUINOLONES; HUMANS; RESPIRATORY TRACT DISEASES;

EID: 33846611355     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Russian source
2. Russian source
3. Ciprofloxacin. Drugs of the future, 1985; 10: 237-241.
4. Ciprofloxacin. Monograph, 1992; 73.
5. Kawahara S., Tada A., Nagara H. et al. Comparison of in vitro antimycobacterial activity of sparfloxacin and other new quinolones. 19th Intern. Congr Chemother, Montreal 1995; Abstr No. 1169.
6. Piddock L. J. Mechanisms of resistance to fluoroquinolones: sttate-of-the-art 1992-1994. Drugs 1995; 49: Suppl. 2: 29-35.
7. The Quinolones. Andriole V. T., ed., London-New-York, 1988; 262.
8. Quinolone antimicrobial agents. Hooper D. C., Wolfson J. S., eds., Washington, 1993; 459.
9. Hoshino K., Sato K., Akahane K. et al. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother 1991; 35: 309-312.
10. Hoshino K., Sato K., Ute T. et al. Inhibitory effects of quinolones on DNA of E.coli and topoisomerase II of fetal calf thymus. Ibid; 1989; 33: 1816-1818.
11. Sato K., Hoshino K., Ute T. et al. Inhibitory effects of ofloxacine on DNA gyrase of E.coli and topoisomerase II of bovine calf thymus. Rev Inf Dis 1989; 11: Suppl. 5: 915-916.
12. Hooper D. C. Quinolone mode of action. Drugs 1995; 49: Suppl. 2: 10-15.
13. Duboia J., St-Pierre C., Gentile C. Post-antibiotic effect and human monocytes activity of trovofloxacin against Legionella spp. 36th Int. Conf Antimicrob Agents Chemother, New Orleans, 1996; Abstr No. A-92.
14. Hoban H. J., Karlovsky J. A., Kabani A. M. et al. The postantibiotic effect (PAE) of sparfloxacin against respiratory tract pathogen. Ibid; Abstr No. A-93.
15. Mingues T., Ramos C., Barrientos S. et al. The postantibiotic effect of ciprofloxacin compared with that of five quinolones. Chemotherapy (Basel), 1991; 37: 420-425.
16. Abalia I., Rodrigues E., Umaran A. et al. Effect of ciprofloxacin on p-fimbriation in uropathogenic E.coli. 1st Eur. Congr Chemother, Glasgow, 1996; Abstr No. W-197.
17. Grimwood K., To M., Rabin H. R. et al. Inhibition of P.aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrob Agents Chemother 1989; 33: 1141-1147.
18. Aujard Y., Gendrel D. Les Quinolones en pediatrie. Paris, Flammarion, 1994; 124.
19. Camp K. A., Miyagi S. L., Schroeder D. J. Patential quinolone-induced cartilage toxicity in children. Ann Pharmacother 1994; 28: 336-338.
20. Danisovicova A., Brezina M., Belan S. et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. Chemotherapy (Basel), 1994; 40: 209-214.
21. Russian source
22. Appelbaum P. C., Spangler S. K., Jacobs M. R. Susceptibility of penicillin-susceptible and penicillin-resistance strains of S.pneumoniae to sparfloxacin, WIN-57273, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Inf Dis, Proc. 3rd Intern Symp, New Quinolones, Ofloxacin, Vancouver, 1990; 17-18.
23. Dougherty T. J., Sankkonen J. J. Membrane permeability changes associated with DNA gyrase inhibitors in E.coli. Antimicrob Agents Chemother 1985; 28: 200-206.
24. Giamarellou H., Galan I., Xirouchaki E. Mechanisms of quinolone resistance in K.pneumoniae multiresistant strains isolated in Greece. 7th Eur Congr Clin Microbiol Inf Dis, Vienna, 1995; Abstr No. 708.
25. Yassien M., Toama M., Watabek K. et al. The role of outer membrane permeability and efflux pump of multiresistant gram-negative clinical isolates in their susceptibility to ciprofloxacin. Ibid; 1995; Abstr 704.
26. Rennie R., Richardson H., Braun N. et al. Comparison of quinolone MICs for P.aeruginosa and other gram-negative non-fermentes isolated from cystic fibrosis patients before and after exposure to ciprofloxacin. 19th Intern Congr. Chemotherapy., Montreal, 1995; Abstr 2054.
27. Hampel B. Clinical needs in the millennium - rhinosinusitis - the role of moxifloxacin. 1st Intern. Moxifloxacin Symp., Berlin 1999; Ed. Mandell L. 2000; p. 174-177.
28. Russian source
29. Burke O., Villanueva C., Mariano H. et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Therap 1999; 21: 1664-1677.
30. Russian source
31. Russian source
32. Russian source
33. Russian source
34. Fang I. W., Chiu B., Viira E. et al. Influence of clarithromycin on early atherosclerotic lesions after C.pneumoniae infection in a rabbit model. Antimicrob Agents Chemother 2002; 46: 2321-2326.
35. Sade J., Lang R., Goshen S. et al. Ciprofloxacin treatment of malignant external otitis. Amer J Med 1989; 87: Suppl. 5A: 138-141.
36. Rolston K. V. I., Haron E., Cunningham C. et al. Intravenosus ciprofloxacin for infections in cancer patients. Amer J Med 1989; 87: Suppl. 5A: 261-265.
37. Baba S. Clinical evaluation of ciprofloxacin in the field of surgery, obstetrics and gynecology, dermatology, otorhinolaryngology, and ophthalmology. Proc Workshop held at the 14th Intern Congr Chemother, Kyoto, 1985; 1985; 71-79.
38. Russian source
39. Wilson A. P. R., Grunenberg R. N. Ciprofloxacin: 10 years of clinical experience. Maxim Medical, 1997; 275.
40. Legent F., Bordure P., Blauvillain C. et al. A double-blind comparison of ciprofloxacin and amoxicillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy 1994; 40: Suppl 1: 8-15.
41. Davies B. I., Maesen F. P. V., Baur C. et al. Clinical efficacy of various dosage regimens of ciprofloxacin in chronic bronchitis. 1st Intern. Ciprofloxacin Workshop, Neu H. C., Weuta H., eds. Leverkusen, 1985; 248-251.
42. Russian source
43. Russian source
44. Russian source
45. Russian source
46. Russian source
47. Hospital-acquired Pneumonia in Adults: Diagnosis, Assessment of Severity, Initial Antimicrobial Therapy, and Preventative Strategies. A Consensus Statement. Official Statement of the American Thoracic Society was Adopted by the ATS Board of Directors, November 1995.
48. Guidelines for prevention of nosocomial pneumonia. Center for Disease Control and Prevention. MMWR. 1997; 46: R1: 1-79.
49. Tablan O. C., Anderson L. J., Besser R. et al. Recommendations of CDC and Health-Care Infection Control Practices Advisory Committee: Guidelines for preventing health-care-associated pneumonia, 2003. Morb Mortal Wkly Rep 2004; 53(RR-3): 1-36.
50. Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated and health-care associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
51. Craven D. E., Palladino R., McQuillen D. P. Health-Care associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 2004; 18: 939-962.
52. Iregui M., Ward S., Sherman G. et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator- associated pneumonia. Chest 2002; 122: 262-268.
53. Niederman M. S. Therapy of ventilator-associated pneumonia: What more can we do to use less antibiotics? Crit Care Med. 2004; 32: 2344-2345.
54. Chrysanthopoulos C. J., Scotelis A. T., Starakis J. C. et al. Use of intravenous ciprofloxacin in respiratory tract infections and biliary sepsis. Amer J Med 1987; 82: Suppl. 4A: 355-359.